FOR IMMEDIATE RELEASE
Dec. 8, 2021
WASHINGTON — Patients Rising today hosted a discussion lab to examine the economic causes behind the delayed adoption of biosimilars, and policy solutions to increase patient access to other lower-priced alternatives. The entire discussion will remain on the Patients Rising website for patients to view and learn how to take action.
The discussion, Towards a Biosimilar Future – Safety, Savings, Solutions, explores the cost savings of biosimilars, policies to expand use, and how to ensure that patients can directly benefit from and see these savings. Thought leaders and patient advocates can learn about the current landscape of biosimilars, and how increased market competition can drive down costs for healthcare systems.
“Everyone knows that cost and healthcare are major issues for many families in this country and for many patients. And especially those who have chronic illnesses who are going to be taking these medications every month. Any kind of savings that they can garner in that process is a benefit to them,” said panelist Terry Wilcox, co-founder and executive director of Patients Rising.
Wilcox was joined for the discussion lab by Peter Pitts, president of the Center for Medicine in the Public Interest and former FDA associate commissioner, and Wayne Winegarden, PhD., director of Pacific Research Institute’s Center for Medical Economics and Innovation. The conversation was moderated by Dr. Robert Popovian, pharmacist and healthcare economist.
The discussion lab is one of several biologic and biosimilar resources available to patients, caregivers, and advocates through the Patients Rising website. The curated library of biosimilar tools includes an E-book, patient surveys, podcast episodes, articles, and patient stories. Explore the full biosimilar module.
